CARA THERAPEUTICS, INC. (NASDAQ:CARA) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

CARA THERAPEUTICS, INC. (NASDAQ:CARA) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March6, 2018, Dean Slagel, a member of the Board of Directors (the “Board”) of Cara Therapeutics, Inc. (the “Company”), delivered his notice of resignation to the Board, effective as of March7, 2018. Mr.Slagel’s decision to resign was not as a result of any disagreement with the Company. Prior to his resignation, Mr.Slagel was the longest tenured director of the Company, having joined the Board in connection with Esperante AB’s initial investment in the Company in 2005. The Board thanks Mr.Slagel for his many years of leadership and service to the Company.


About CARA THERAPEUTICS, INC. (NASDAQ:CARA)

Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. The Company is engaged in developing product candidates that focus on the body’s peripheral nervous system. Its product candidate pipeline includes I.V. CR845 for acute pain; I.V. CR845 for uremic pruritus; Oral CR845, and CR701. The Company’s I.V. CR845 is an injectable version of peripheral kappa opioid receptor agonist, which is intended for the treatment of acute pain in an acute care setting. The Company is developing an oral version of CR845 for the treatment of moderate-to-severe acute and chronic pain. The Company’s CR701 is a peripherally-restricted, mixed-CB1/CB2 receptor agonist that interacts with cannabinoid receptor subtypes, with no off-target activities. CR701 is in preclinical-stage of development.

An ad to help with our costs